Navigation Links
Patient Safety Technologies Reports First Quarter 2011 Results
Date:5/23/2011

S, INC.Consolidated Balance SheetsMarch 31, 2011(unaudited)December 31, 2010AssetsCurrent assetsCash and cash equivalents$

6,089,395$

1,896,034Restricted cash223,630223,630Accounts receivable457,153772,381Inventory, net927,6771,110,832Prepaid expenses62,404104,628Total current assets7,760,2594,107,505Property and equipment, net930,474979,833Goodwill1,832,0271,832,027Patents, net2,707,8472,789,083Other assets43,98839,038Total assets$

13,274,595$

9,747,486Liabilities and Stockholders' EquityCurrent liabilitiesAccounts payable$

618,252$

2,605,669Warrant derivative liability781,420991,682Deferred revenue869,1631,477,720Accrued liabilities864,679942,472Total current liabilities3,133,5146,017,543Stockholders' equity Total stockholders' equity10,141,0813,729,943Total liabilities and stockholders' equity $

13,274,595$

9,747,486PATIENT SAFETY TECHNOLOGIES, INC.Consolidated Statements of OperationsFor the Three months Ended March 31,2011 (unaudited)2010 (unaudited)Revenues$

1,970,656$

2,364,819Cost of revenue1,041,1011,088,887Gross profit929,5551,275,932Operating expenses:Research and development29,46233,331Sales and marketing659,036994,116General and administrative1,071,8961,651,861Total operating expenses1,760,3942,679,308Operating loss(830,839)(1,403,376)Other incomeInterest expense(4,192)(6,333)Gain on change in fair value of warrant derivative liability210,2621,718,738Other income—51,944Total other income206,0701,764,349Income (loss) before income taxes(624,769)360,973Income tax (provision) benefit(3,773)32,573Net income (loss)(628,542)393,546Preferred dividends(123,959)(19,163)Net income (loss) applicable to common shareholders$

(752,501)$

374,383Income (loss) per common shareBasic$

(0.03)$

0.02Diluted$

(0.03)$

0.01Weighted average common shares outstanding:Basic 24,200,78523,456,063Diluted24,200,78525,199,632
'/>"/>

SOURCE Patient Safety Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
7. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
10. Many Heart Attack Patients Dont Get Best Emergency Treatment
11. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... SAN DIEGO, April 30, 2015  Tandem Diabetes Care ® ... and manufacturer of the t:slim ® and t:flex™ Insulin ... March 31, 2015. In comparing the first ... , Sales grew 53 percent to $12.3 million from $8.1 ... 2,487 pumps from 1,723 pumps "Our investment in ...
(Date:4/30/2015)... , April 30, 2015   Regulus Therapeutics ... leading the discovery and development of innovative medicines targeting ... and highlights for the quarter ended March 31, 2015 ... markets close. Regulus will host a ... at 5:00 pm Eastern Daylight Time to discuss its ...
(Date:4/30/2015)... (Nasdaq: DRRX ) announced today financial results for ... million and net loss was $4.9 million for the ... total revenues of $6.3 million and net loss of ... 2014.At March 31, 2015, we had cash and investments ... $34.9 million at December 31, 2014.  Subsequent to quarter-end, ...
Breaking Medicine Technology:Tandem Diabetes Care Reports First Quarter 2015 Financial Results 2Tandem Diabetes Care Reports First Quarter 2015 Financial Results 3Tandem Diabetes Care Reports First Quarter 2015 Financial Results 4Tandem Diabetes Care Reports First Quarter 2015 Financial Results 5Tandem Diabetes Care Reports First Quarter 2015 Financial Results 6Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 2Regulus Announces Timing for First Quarter 2015 Financial Results Webcast and Conference Call 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 2DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 3DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 4DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 5DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 6DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 7DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 8DURECT Corporation Announces First Quarter 2015 Financial Results and Update of Programs 9
... 2012  At the 2012 American Association of Neurological ... the Miami Beach Convention Center, Elekta (booth #725) ... Knife® Perfexion™ that promise to enhance information ... us the opportunity to demonstrate to neurological surgeons ...
... PITTSBURGH, April 13, 2012 Mylan Inc. (Nasdaq: ... Pharmaceuticals Inc. has received final approval from the U.S. ... Drug Application (ANDA) for Fluvastatin Capsules USP, 20 mg ... Lescol ® Capsules. This product is indicated for ...
Cached Medicine Technology:Elekta to Unveil New Neuroscience Solution for Leksell Gamma Knife at 2012 AANS Meeting 2Mylan Launches First Generic Version of Lescol® Capsules 2
(Date:5/2/2015)... Ticket Down has secured additional inventories of authentic ... event today, Saturday, May 2nd at the MGM Grand Garden ... able to secure tickets for both the actual fight and ... have wanted for more than five years was finally been ... step inside the ring to fight Manny “Pac-Man” Pacquiao in ...
(Date:5/2/2015)... May 02, 2015 We are pleased ... Delray Recovery Center as one of the Top Workplaces ... in the addiction treatment field for their ethics and ... innovate and to continue their educational efforts. The Delray ... environment, never forgetting their purpose – to help individuals ...
(Date:5/2/2015)... 2015 ZoomCare, the Portland-based innovator of ... to offer its new healthcare insurance to individuals and ... Health Insurance System is the nation’s first health insurance ... performance. ZOOM+ Personal Health Insurance was ZoomCare’s first such ... are subject to review and regulation by the Oregon ...
(Date:5/1/2015)... Jusuru International has been awarded the prestigious 2015 ... flagship nutritional supplement, Liquid BioCell™ Life, and the relaunch ... logo, new packaging, new products, and new messaging. ... and promote programs that serve as examples of direct ... International for their outstanding accomplishments and contributions to direct ...
(Date:5/1/2015)... NJ (PRWEB) May 01, 2015 Hope ... continued support of Hope For The Warriors® and military ... $20K to support Hope For The Warriors®, a national ... the family unit, and restoring hope for our service ... autograph signings, All American Ford collected and matched small ...
Breaking Medicine News(10 mins):Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 2Health News:Cheap Floyd Mayweather vs. Manny Pacquiao Tickets: Ticket Down Has Last Minute Tickets for Mayweather vs. Pacquiao at the MGM Grand Garden Arena in Las Vegas 3Health News:The Delray Recovery Center Named 2015 Top Workplace 2Health News:ZoomCare Applies to be on Oregon Exchange 2Health News:Jusuru International Receives 2015 DSA Ethos Award 2Health News:Jusuru International Receives 2015 DSA Ethos Award 3Health News:Jusuru International Receives 2015 DSA Ethos Award 4Health News:Jusuru International Receives 2015 DSA Ethos Award 5Health News:All American Ford Presents Donation to Nonprofit Hope For The Warriors 2
... five whites could carry a genetic variant that substantially increases ... to new research. This genetic variant, characterized by one ... response to specific chemical signals. In the study, led by ... more than threefold increase in the odds that carriers will ...
... HealthDay Reporter , MONDAY, Dec. 20 (HealthDay News) -- New research ... -- contain a fatty acid that may lower the risk of ... according to the study in the Dec. 21 issue of the ... blood levels of this fatty acid reduce their odds of diabetes ...
... TUESDAY, Dec. 21 (HealthDay News) -- Judy Brown says she has ... Brown, now 51 and living in Nashua, N.H., remembers being ... come on, even though she didn,t understand at the time what ... she said. "Sometimes it would be a car, a back seat ...
... people with early stage liver cancer were more likely than ... new study from the University of Michigan Comprehensive Cancer Center. ... cancer patients were alive but only 15 percent of Hispanic ... times ranged from 10 months for whites and Hispanics to ...
... monitoring helped push cure rates to nearly 88 percent ... Research Hospital acute lymphoblastic leukemia (ALL) treatment protocol and ... battling the most common childhood cancer. A report ... of Clinical Oncology noted that overall survival jumped 30 ...
... By Steven Reinberg HealthDay Reporter , MONDAY, ... among Americans, a new study shows, despite reported links to ... safe "spray-on" tans. In fact, about one in every ... they use indoor tanning, University of Minnesota researchers report. ...
Cached Medicine News:Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 2Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 3Health News:Genetic trait could triple odds of whites' susceptibility to heavy cocaine abuse 4Health News:Whole-Fat Dairy Products May Lower Type 2 Diabetes Risk: Study 2Health News:Whole-Fat Dairy Products May Lower Type 2 Diabetes Risk: Study 3Health News:A Lifetime of Migraines 2Health News:Blacks with liver cancer more likely to die, study finds 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 2Health News:Intensive chemotherapy can dramatically boost survival of older teenage leukemia patients 3Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 2Health News: Tanning Beds Still Popular Despite Skin Cancer Risk 3
... basic Thermomixer is a compact model that ... x 1.5 ml tubes. Impressive features of ... design, and high stabilityeven at maximum mixing ... gentle to vigorous mixing, including intermittent mixing; ...
... ug Strept. 25 ug Fungizone ... and Buffer products are manufactured ... and are cell culture tested ... Properties, Sterility : Neg. , ...
... 25,000 units Penicillin/25,000 ... Cell Culture Reagent and ... in accordance with cGMP ... culture tested to assure ...
Penicillin-Streptomycin-Glutamine (100X) liquid...
Medicine Products: